Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...